McBride, Jacqueline M <br/><br/>
Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.  [electronic resource] 

 -  Arthritis and rheumatism  Nov 2012 
 - 3666-76 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1529-0131 
<br/><br/><label>Standard No.: </label>10.1002/art.34632  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Antibodies, Antinuclear--blood<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>Antibodies, Neutralizing--administration & dosage<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Female<br/>Genome-Wide Association Study<br/>Humans<br/>Immunoglobulin G--administration & dosage<br/>Injections, Intravenous<br/>Interferons--genetics<br/>Lupus Erythematosus, Systemic--drug therapy<br/>Male<br/>Middle Aged<br/>Placebos<br/>Severity of Illness Index<br/>Transcriptome<br/>Treatment Outcome<br/>Young Adult